Management and Survival of Pleural Mesothelioma: A Record Linkage Study

Background: Pleural mesothelioma (PM) is a rare, highly lethal tumor. A definite consensus on its management has yet to be established. Objectives: To assess management, overall survival (OS), and their predictors in a cohort of patients from Lombardy, the largest Italian region (about 10 million inhabitants). Methods: Through a record linkage between Lombardy health care administrative databases, we identified patients diagnosed with PM in 2006–2011 without history of cancer, evaluating their management. OS from PM diagnosis was estimated using the Kaplan-Meier method. Predictors of OS and of treatment were assessed using Cox regression models with time-dependent covariates when appropriate. Results: Out of 1,326 patients, 754 (56.9%) received treatment for PM: 205 (15.5%) underwent surgery, and 696 (52.5%) used chemotherapy. Surgery was spread across several hospitals, and most patients diagnosed in nonspecialized centers (70%) underwent surgery in the same centers. Age at diagnosis was a strong inverse determinant of surgery. Determinants of receiving chemotherapy were younger age, a more recent first diagnosis, and first diagnosis in a specialized center. OS was 45.4% at 1 year, 24.8% at 2 years, and 9.6% at 5 years (median 11 months). OS decreased with age, and was higher for those who underwent surgery, but not for those treated with chemotherapy. Conclusions: Management of PM varied widely in clinical practice, and significant predictors of treatment were younger age and recent diagnosis, though a high proportion of patients were not treated. Patients were treated in various hospitals, indicating the importance of concentrating serious rare neoplasms in Comprehensive Cancer Centers (as recognized by the Italian Health Ministry).

[1]  Giovanni Corrao,et al.  Building reliable evidence from real-world data: methods, cautiousness and recommendations , 2022, Epidemiology, Biostatistics, and Public Health.

[2]  C. la Vecchia,et al.  International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision , 2017, Journal of global oncology.

[3]  A. Santoro,et al.  Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[4]  T. Brüning,et al.  Incidence of malignant mesothelioma in Germany 2009–2013 , 2017, Cancer Causes & Control.

[5]  Nick A Maskell,et al.  Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment , 2016, European Respiratory Review.

[6]  J. Peto,et al.  Consensus Report of the 2015 Weinman International Conference on Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  C. la Vecchia,et al.  Updated mortality study of a cohort of asbestos textile workers , 2016, Cancer medicine.

[8]  J. V. van Meerbeeck,et al.  Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. , 2015, Lung cancer.

[9]  A. Husain,et al.  Malignant Mesothelioma Diagnosis. , 2015, Archives of pathology & laboratory medicine.

[10]  M. Berry,et al.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. , 2015, The Journal of surgical research.

[11]  G. Corrao,et al.  A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case–control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology , 2015, BMJ Open.

[12]  I. Opitz Management of malignant pleural mesothelioma-The European experience. , 2014, Journal of thoracic disease.

[13]  V. Torri,et al.  Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  A. Schnatter,et al.  Mesothelioma in Occupational Cohort Studies: Methodological Considerations , 2014, Journal of occupational and environmental medicine.

[15]  G. Corrao,et al.  A new scope and a vision for record linkage studies , 2013, Epidemiology, Biostatistics, and Public Health.

[16]  E. Negri,et al.  Clinical use, safety and effectiveness of novel high cost anticancer therapies after marketing approval: a record linkage study , 2013, Epidemiology, Biostatistics, and Public Health.

[17]  V. Rusch,et al.  Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  V. Rusch,et al.  The MARS feasibility trial: conclusions not supported by data. , 2011, The Lancet. Oncology.

[19]  J. Peto,et al.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study , 2011, The Lancet. Oncology.

[20]  R. Stahel,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  C. Ragazzo Regione Lombardia capo fila nel File F , 2009 .

[22]  F. Galateau-Sallé,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[23]  Samy Suissa,et al.  Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.

[24]  C. Gridelli,et al.  Multidisciplinary treatment of malignant pleural mesothelioma. , 2007, The oncologist.

[25]  K. McPherson,et al.  An age, period and cohort analysis of pleural cancer mortality in Europe. , 2000 .

[26]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[27]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[28]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.

[29]  R. Alfieri,et al.  New therapeutic strategies for malignant pleural mesothelioma , 2017, Biochemical pharmacology.

[30]  C. la Vecchia,et al.  Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. , 2012, The oncologist.

[31]  F. Ricceri,et al.  Survival of pleural malignant mesothelioma in Italy: A population‐based study , 2009, International journal of cancer.

[32]  C. la Vecchia,et al.  An age, period and cohort analysis of pleural cancer mortality in Europe. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[33]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.

[34]  R. Deyo,et al.  ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES , 1992 .

[35]  Paul L. Grimaldi,et al.  Diagnosis related groups: A practitioner's guide , 1982 .